Reporter: Chenjie XU, Associate Professor

Time：December 29, 2021, 10:00 a.m.

Place：Tencent Meeting，Number：333-496-523

Welcome to attend the seminar!

School for Radiological＆Interdisciplinary Sciences, Soochow University

Short Bio:

Dr. XU Chenjie got his PhD, Master, and BS from Brown University (2009), HKUST (2004), Nanjing University (2002) respectively. He had conducted research at Stanford University (2005), Brigham and Women’s Hospital (2009-2012), and Nanyang Technological University (2012-2019). Currently he is an associate professor of biomedical engineering at City University of Hong Kong.

Research Fields and Achievements

Dr. XU is dedicated to the development of transdermal drug delivery formulations and devices (especially nucleic acid-based nanoparticles and microneedle-based skin patch). He is well known for the development of skin patch for keloid treatment, antio-bese skin patch, skin patch for skin interstitial fluid extraction etc. He has published more than 140 peer-reviewed articles (citation is 11k with H index of 45), edited two books, holding 10 international patents, and found two spin-offs. His research is supported by a wide range of public and private foundations including Singapore Minister of Education, Singapore A*Star, Continental Corp (German), Bill & Melinda Gates Foundation, Hong Kong University Grants Committee, National Natural Science Fo-undation of China, etc.

Report Summaries

Microneedles (MNs) are an emerging platform for transdermal applications including drug delivery, insulin delivery, vaccination, biosensing, disease diagnosis, and cosmeceutical industry. Their advantages lie at their easy-to-use, pain-free, minimally invasive, and self-administrable features. This overcomes the skin barrier to enhance transdermal delivery of drugs and biomolecules with different physicochemical properties in vitro, ex vivo and in vivo. In this talk, Dr. Xu will share microneedle technologies developed in his lab for meeting a wide range of medical needs, including keloid treatment and prevention, obesity treatment, dental and eye disease treatment, and immune therapy. He will also present his envision in utilizing MN platform for the in-situ monitoring of physiological signals.